E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Exudative Age-Related Macular Degeneration |
Degenerazione Maculare Senile Essudativa |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025409 |
E.1.2 | Term | Macular degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate efficacy of bevasiranib sodium as maintenance therapy in patients with Exudative Age-Related Macular Degeneration (AMD)after initial VEGF antagonist therapy with 3 doses of Lucentis |
Valutare l'efficacia di bevasiranib sodico come terapia di mantenimento per la Degenerazione Maculare Senile dopo l'inizio di una terapia anti VEGF con tre dosi di Lucentis. |
|
E.2.2 | Secondary objectives of the trial |
The proportion of patients who have a successful visual acuity outcome at week 60 and had no need for rescue therapy in the first year after treatment |
Valutare la proporzione di pazienti con esito positivo per quanto riguarda l'acuita' visiva alla settimana 60 e che non necessitano di terapia di sostegno nel primo anno dopo l'inizio del trattamento |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients must have predominantly classic, minimally classic, or occult
with no classic lesions, secondary to AMD, with a total lesion size
(including blood, scarring and neovascularization) of < 12 total disc areas (30.48 mm2);
2. Patients must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen Equivalent) in the study eye;
3. Occult with no classic lesions must have evidence of presumed recent
disease progression defined as:
a. The presence of subretinal hemorrhage OR
b. Loss of > 1 line of VA during the past 12 weeks OR
c. FA documented lesion growth by _ 10% during the past 12 weeks;
4. Patients must be age 50 or older;
5. Patient must sign and retain a copy of the written informed consent form;
6. Patients must be willing and able to return for scheduled follow-up
examinations for two years; and
7. Women must be post-menopausal 1 year, or surgically sterilized. If not, a negative serum pregnancy test is required within 14 days of randomization. |
Maschi e femmine, eta' minima 50 anni, con lesioni prevalentemente classiche, minimamente classiche o occulte senza classiche secondarie a Degenerazione Maculare Senile e miglior acuita' visiva corretta secondo EDTRS da 69 a 24 lettere (20/40 a 20/320 equivalenti Snellen) |
|
E.4 | Principal exclusion criteria |
1. Patients who have been previously treated for AMD in the study eye with
any agent except vitamins and/or minerals;
2. Patients with concomitant disease in the study eye, including uveitis,
presence of pigment epithelial tears or rips, acute ocular or periocular
infection;
3. Patients with advanced glaucoma (greater than 0.8 cup:disk) or intraocular pressure above 22mmHg in the study eye despite adequate treatment with medication;
4. Patients with any retinal vasculopathies, including diabetic retinopathy,retinal vein occlusions, etc. in the study eye;
5. Patients with any subfoveal scarring, atrophy, or hemorrhage > 500μm in the study eye;
6. Patients whose CNV lesion in the study eye contains more than 25%
scarring and/or fibrosis;
7. Patients with inadequate papillary dilation or significant media opacities in the study eye, which may interfere with visual acuity or the evaluation of the posterior segment, including cataract, which is likely to require surgical intervention within the 100 week active study period;
8. Patients who present with choroidal neovascularlization due to causes
other than AMD, including ocular Histoplasmosis syndrome, angioid
streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia
(spherical equivalent > 8 Diopters or axial length > 25mm);
9. Patients who have undergone any intraocular surgery of the study eye
within 12 weeks prior to the screening visit;
10. Patients who have undergone any extrafoveal/juxtafoveal laser treatment
of the study eye within two weeks prior to the screening visit;
11. Patients with previous posterior vitrectomy of the study eye;
12. Patients with known serious allergies to fluorescein dye, not amenable to treatment with diphenhydramine;
13. Patients who underwent previous radiation therapy to the head or neck in the region of the study eye;
14. Patients who received treatment with any investigational drug within 4
weeks prior to the screening visit;
15. Patients with an intravitreal device or drug implant in the study eye;
16. Patients with any other condition, which in the judgment of the
investigator would prevent the patient from completing the study;
17. Premenopausal women not using adequate contraception. |
I pazienti non devono mai essere stati trattati per la DMS, il che esclude precedente uso di Avastin/Lucentis, Macugen e qualsiasi altro prodotto anti VGEF, trattamenti con steroidi, PDT, trattamenti con radiazioni, qualsiasi trattamento sperimentale per la DMS. I pazienti non possono essere stati sottoposti a nessuna chirurgia intraoculare entro 12 settimane dallo screening. Una precedente vitrectomia posteriore nell'occhio in studio non e' ammessa. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of patients at week 60 in each group with a successful visual acuity outcome (as defined as avoidance of a 3, or more, line loss in vision) |
La proporzione di pazienti in ciascun gruppo alla settimana 60 con esito positivo per quanto riguarda l'acuita' visiva (definito come prevenzione della perdita di 3 o piu' linee nella visione) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
La conclusione della sperimentazione si identifica con la Visita di Chiusura dell'ultimo centro attivo |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 36 |
E.8.9.2 | In all countries concerned by the trial days | 0 |